Ocuphire Pharma Investor Presentation Deck

Percent of Subjects With ≥ 2-Step Improvement in DRSS From Baseline ZETA-1 Did Not Meet the Week 24 Phase 2 Primary Endpoint (based on Anti-VEGF Precedence for DR) Ocuphire Percent of Subjects (%) 35% 30% 25% 20% 15% 10% 5% 0% Percent of Subjects With ≥ 2-step Improvement in DRSS From Baseline by Visit (mITT) - Study Eye 0% n=48 p=0.27 4% n=47 Week 12 Visit ■Placebo (N=50) 7% n=41 p=0.98 8% ■APX3330 (N=48) n=39 Week 24 ZETA-1 Clinical Trial Note: Large "N" indicates total number of participants within each arm for the mITT population. Small "n" indicates total number of evaluable eyes for each respective endpoint and arm. 22

View entire presentation